# A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

> **NCT06189391** · PHASE1 · RECRUITING · sponsor: **MSD R&D (China) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** MK-1045

## Key facts

- **NCT ID:** NCT06189391
- **Lead sponsor:** MSD R&D (China) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-16
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06189391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06189391, "A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06189391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*